EGF+61 A>G polymorphism does not predict response to first‐generation EGFR tyrosine kinase inhibitors in lung cancer patients

by Leticia F. Leal, Ana C. Laus, Rodrigo Cavagna, Flavia E. dePaula, Marco A. deOliveira, Dayana M. Ribeiro, Fernanda M. Hassan, José E. Miziara, Eduardo C. Albino daSilva, Vinicius D. daSilva, Pedro De Marchi, Rui M. Reis
Published 2020-10-01